1-(2-(2H-1,2,3-triazol-2-yl)phenyl)ethanone | 1544799-59-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-(2H-1,2,3-triazol-2-yl)phenyl)ethanone
• 英文别名: 1-[2-(Triazol-2-yl)phenyl]ethanone
• CAS: 1544799-59-8
• 化学式: C₁₀H₉N₃O
• 分子量: 187.201
• InChiKey: JXCWVJZNMKYRSQ-UHFFFAOYSA-N

物化性质

• 沸点：
  361.4±44.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  47.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  glyoxal bis(phenylhydrazone) 在 叔丁基过氧化氢 、 palladium diacetate 、 copper(II) bis(trifluoromethanesulfonate) 作用下， 以 水 、 甲苯 为溶剂， 反应 24.0h， 生成 1-(2-(2H-1,2,3-triazol-2-yl)phenyl)ethanone
  参考文献：
  名称：

  N-Aryl-1,2,3-三唑与醇在水中的区域选择性邻酰化

  摘要：

  N-芳基-1,2,3-三唑的钯催化区域选择性邻位酰化已在水性条件下实现，无需表面活性剂或添加剂的帮助。该反应以苄醇、杂环醇和脂肪醇为酰化剂，叔丁基过氧化氢（TBHP）为氧化剂，为三唑取代的芳基、杂芳基和脂肪酮的合成提供了一条替代途径。优良的产量。

  DOI：

  10.1002/ejoc.201600479

文献信息

• [EN] 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES 2-PYRIDYLOXY-4-ÉTHER DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014137883A1

  公开（公告）日：2014-09-12

  The present invention is directed to 2-pyridyloxy-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved..

  本发明涉及2-吡啶氧基-4-醚化合物，这些化合物是促进睡眠的受体拮抗剂。本发明还涉及在潜在治疗或预防神经系统和精神疾病中使用本文所述的2-吡啶氧基-4-醚化合物。本发明还涉及包括这些化合物的药物组合物。本发明还涉及在预防或治疗涉及促进睡眠的受体的这些疾病中使用这些药物组合物。
• Palladium-Catalyzed Acylation of 2-Aryl-1,2,3-triazoles with Aldehydes
  作者：Zechao Wang、Qinshan Tian、Xin Yu、Chunxiang Kuang

  DOI：10.1002/adsc.201300912

  日期：2014.3.24

  The palladium‐catalyzed acylation of 2‐aryl‐1,2,3‐triazoles with aldehydes via CH bond activation is described. A wide variety of products was isolated in good to excellent yields. This finding provides a new and useful strategy for the synthesis of aromatic ketones.

  的2-芳基-1,2,3-三唑与醛钯催化酰化经由Ç  H键活化进行说明。分离出多种产品，收率良好至优异。这一发现为芳族酮的合成提供了一种新的有用的策略。
• 2-PYRIDYLOXY-4-ESTER OREXIN RECEPTOR ANTAGONISTS
  申请人：KUDUK Scott D.

  公开号：US20160214960A1

  公开（公告）日：2016-07-28

  The present invention is directed to 2-pyridyloxy-4-ester compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ester compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶氧基-4-酯化合物，其是睡眠荷尔蒙受体拮抗剂。本发明还涉及使用此处所述的2-吡啶氧基-4-酯化合物在潜在的涉及睡眠荷尔蒙受体的神经和精神障碍和疾病的治疗或预防中。本发明还涉及包含这些化合物的药物组合物。本发明还涉及使用这些药物组合物在预防或治疗涉及睡眠荷尔蒙受体的这些疾病中。
• 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS
  申请人：KUDUK Scott D.

  公开号：US20160016935A1

  公开（公告）日：2016-01-21

  The present invention is directed to 2-pyridyloxy-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶氧基-4-醚类化合物，其为促进睡眠荷尔蒙受体的拮抗剂。本发明还涉及使用此处所述的2-吡啶氧基-4-醚类化合物在潜在的神经和精神障碍和疾病的治疗或预防中，其中促进睡眠荷尔蒙受体发挥作用。本发明还涉及包含这些化合物的药物组合物。本发明还涉及使用这些药物组合物在预防或治疗促进睡眠荷尔蒙受体发挥作用的疾病中。
• HALO AND TRIFLUOROMETHYL SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160068514A1

  公开（公告）日：2016-03-10

  The present invention is directed to halo and trifluoromethyl substituted compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及卤代和三氟甲基取代化合物，其为促进素受体拮抗剂。本发明还涉及所述化合物在潜在的神经系统和精神疾病的治疗或预防中的用途，其中促进素受体参与其中。本发明还涉及包含这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗促进素受体参与的这些疾病中的用途。